{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:55:03Z","timestamp":1793318103910,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272038"],"award-info":[{"award-number":["82272038"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00259-025-07628-x","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T02:37:08Z","timestamp":1760927828000},"page":"1913-1926","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Fully automated volumetric assessment of tumor burden using artificial intelligence on 68Ga-PSMA-11 PET predicts survival after 177Lu-PSMA therapy in metastatic Castration-resistant prostate cancer"],"prefix":"10.1007","volume":"53","author":[{"given":"Shiming","family":"Zang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingle","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lele","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudan","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youdan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruipeng","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Cahid","family":"Civelek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"7628_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"7628_CR2","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.annonc.2024.01.011","volume":"35","author":"D Olmos","year":"2024","unstructured":"Olmos D, Lorente D, Alameda D, Cattrini C, Romero-Laorden N, Lozano R, et al. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes. Ann Oncol. 2024;35:458\u201372.","journal-title":"Ann Oncol"},{"key":"7628_CR3","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2967\/jnumed.120.257238","volume":"62","author":"A Farolfi","year":"2021","unstructured":"Farolfi A, Calderoni L, Mattana F, Mei R, Telo S, Fanti S, et al. Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate cancer. J Nucl Med. 2021;62:596\u2013604.","journal-title":"J Nucl Med"},{"key":"7628_CR4","doi-asserted-by":"publisher","DOI":"10.1177\/1536012118776068","volume":"17","author":"K Rahbar","year":"2018","unstructured":"Rahbar K, Afshar-Oromieh A, Jadvar H, Ahmadzadehfar H. PSMA theranostics: current status and future directions. Mol Imaging. 2018;17:1536012118776068.","journal-title":"Mol Imaging"},{"key":"7628_CR5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1053\/j.semnuclmed.2019.07.003","volume":"50","author":"H Ahmadzadehfar","year":"2020","unstructured":"Ahmadzadehfar H, Rahbar K, Essler M, Biersack HJ. PSMA-based theranostics. A step-by-step practical approach to diagnosis and therapy for mCRPC patients. Semin Nucl Med. 2020;50:98\u2013109.","journal-title":"Semin Nucl Med"},{"key":"7628_CR6","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797\u2013804.","journal-title":"Lancet"},{"key":"7628_CR7","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103.","journal-title":"N Engl J Med"},{"key":"7628_CR8","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.eururo.2018.11.016","volume":"75","author":"MM Heck","year":"2019","unstructured":"Heck MM, Tauber R, Schwaiger S, Retz M, D\u2019Alessandria C, Maurer T, et al. Treatment Outcome, Toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic Castration-resistant prostate cancer. Eur Urol. 2019;75:920\u20136.","journal-title":"Eur Urol"},{"key":"7628_CR9","doi-asserted-by":"publisher","first-page":"835956","DOI":"10.3389\/fonc.2022.835956","volume":"12","author":"T Bu","year":"2022","unstructured":"Bu T, Zhang L, Yu F, Yao X, Wu W, Zhang P, et al. 177Lu-PSMA-I&T radioligand therapy for treating metastatic Castration-Resistant prostate cancer: A Single-Centre study in East Asians. Front Oncol. 2022;12:835956.","journal-title":"Front Oncol"},{"key":"7628_CR10","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/ajco.13944","volume":"20","author":"WM Chua","year":"2024","unstructured":"Chua WM, Lam WW, Tong AK, Sultana R, Kua SMY, Kanesvaran R, et al. Outcomes and prognostic predictors of Lu-177 PSMA radioligand therapy in metastatic castration-resistant prostate cancer (Asian population study). Asia Pac J Clin Oncol. 2024;20:572\u201381.","journal-title":"Asia Pac J Clin Oncol"},{"key":"7628_CR11","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.2967\/jnumed.120.242057","volume":"61","author":"R Seifert","year":"2020","unstructured":"Seifert R, Herrmann K, Kleesiek J, Sch\u00e4fers M, Shah V, Xu Z, et al. Semiautomatically quantified tumor volume using 68Ga-PSMA-11 PET as a biomarker for survival in patients with advanced prostate cancer. J Nucl Med. 2020;61:1786\u201392.","journal-title":"J Nucl Med"},{"key":"7628_CR12","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","volume":"48","author":"R Seifert","year":"2021","unstructured":"Seifert R, Kessel K, Schlack K, Weber M, Herrmann K, Spanke M, et al. PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis. Eur J Nucl Med Mol Imaging. 2021;48:1200\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7628_CR13","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6560\/abb6bd","volume":"65","author":"AJ Weisman","year":"2020","unstructured":"Weisman AJ, Kieler MW, Perlman S, Hutchings M, Jeraj R, Kostakoglu L, et al. Comparison of 11 automated pet segmentation methods in lymphoma. Phys Med Biol. 2020;65:235019.","journal-title":"Phys Med Biol"},{"key":"7628_CR14","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1038\/s42256-024-00912-9","volume":"6","author":"S Gatidis","year":"2024","unstructured":"Gatidis S, Fr\u00fch M, Fabritius MP, Gu S, Nikolaou K, Foug\u00e8re CL, et al. Results from the autopet challenge on fully automated lesion segmentation in oncologic PET\/CT imaging. Nat Mach Intell. 2024;6:1396\u2013405.","journal-title":"Nat Mach Intell"},{"key":"7628_CR15","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2967\/jnumed.123.267048","volume":"65","author":"KH Leung","year":"2024","unstructured":"Leung KH, Rowe SP, Sadaghiani MS, Leal JP, Mena E, Choyke PL, et al. Deep semisupervised transfer learning for fully automated whole-body tumor quantification and prognosis of cancer on PET\/CT. J Nucl Med. 2024;65:643\u201350.","journal-title":"J Nucl Med"},{"key":"7628_CR16","volume":"5","author":"J Wasserthal","year":"2023","unstructured":"Wasserthal J, Breit HC, Meyer MT, Pradella M, Hinck D, Sauter AW, et al. Totalsegmentator: robust segmentation of 104 anatomic structures in CT images. Radiology: Artificial Intelligence. 2023;5:e230024.","journal-title":"Radiology: Artificial Intelligence"},{"key":"7628_CR17","doi-asserted-by":"publisher","first-page":"555","DOI":"10.2967\/jnumed.123.266742","volume":"65","author":"J Shi","year":"2024","unstructured":"Shi J, Li D, Chen M, Fu Y, Peng S, Zhang Q, et al. The value of 68Ga-PSMA PET\/MRI for classifying patients with PI-RADS 3 lesions on multiparametric MRI: a prospective single-center study. J Nucl Med. 2024;65:555\u20139.","journal-title":"J Nucl Med"},{"key":"7628_CR18","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.233460","volume":"312","author":"PH Kuo","year":"2024","unstructured":"Kuo PH, Morris MJ, Hesterman J, Kendi AT, Rahbar K, Wei XX, et al. Quantitative 68Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following 177Lu-PSMA-617 (VISION trial). Radiology. 2024;312:e233460.","journal-title":"Radiology"},{"key":"7628_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2967\/jnumed.124.268167","volume":"66","author":"RA Demirci","year":"2025","unstructured":"Demirci RA, Ghodsi A, Gulati R, Behnia S, Nelson PS, Cheng HH, et al. Pet-based therap eligibility and outcomes of VISION-eligible patients with metastatic castration-resistant prostate cancer who received 177Lu-PSMA-617: importance of 18F-FDG-avid discordant findings. J Nucl Med. 2025;66:47\u201353.","journal-title":"J Nucl Med"},{"key":"7628_CR20","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1007\/s00259-020-04723-z","volume":"47","author":"J Ferdinandus","year":"2020","unstructured":"Ferdinandus J, Violet J, Sandhu S, Hicks RJ, Ravi Kumar AS, Iravani A, et al. Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. Eur J Nucl Med Mol Imaging. 2020;47:2322\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7628_CR21","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1007\/s00259-023-06163-x","volume":"50","author":"M Kim","year":"2023","unstructured":"Kim M, Seifert R, Fragemann J, Kersting D, Murray J, Jonske F, et al. Evaluation of thresholding methods for the quantification of [68Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [177Lu]Lu-PSMA-617 radioligand therapy. Eur J Nucl Med Mol Imaging. 2023;50:2196\u2013209.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7628_CR22","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S0895-4356(01)00341-9","volume":"54","author":"EW Steyerberg","year":"2001","unstructured":"Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol. 2001;54:774\u201381.","journal-title":"J Clin Epidemiol"},{"key":"7628_CR23","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","volume":"22","author":"A Gafita","year":"2021","unstructured":"Gafita A, Calais J, Grogan TR, Hadaschik B, Wang H, Weber M, et al. Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol. 2021;22:1115\u201325.","journal-title":"Lancet Oncol"},{"key":"7628_CR24","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1200\/JCO.2013.52.3696","volume":"32","author":"S Halabi","year":"2014","unstructured":"Halabi S, Lin CY, Kelly WK, Fizazi KS, Moul JW, Kaplan EB, et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2014;32:671\u20137.","journal-title":"J Clin Oncol"},{"key":"7628_CR25","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1093\/jnci\/djt280","volume":"105","author":"S Halabi","year":"2013","unstructured":"Halabi S, Lin CY, Small EJ, Armstrong AJ, Kaplan EB, Petrylak D, et al. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst. 2013;105:1729\u201337.","journal-title":"J Natl Cancer Inst"},{"key":"7628_CR26","doi-asserted-by":"publisher","first-page":"102862","DOI":"10.1016\/j.eclinm.2024.102862","volume":"77","author":"K Herrmann","year":"2024","unstructured":"Herrmann K, Gafita A, de Bono JS, Sartor O, Chi KN, Krause BJ, et al. Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial. EClinicalMedicine. 2024;77:102862.","journal-title":"EClinicalMedicine"},{"key":"7628_CR27","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.3390\/cancers15204907","volume":"15","author":"S Gaal","year":"2023","unstructured":"Gaal S, Huang K, Rogasch JMM, Jochens HV, De Santis M, Erber B, et al. Prognostic value of the de Ritis ratio for overall survival in patients with metastatic Castration-Resistant prostate cancer undergoing [177Lu]Lu-PSMA-617 radioligand therapy. Cancers (Basel). 2023;15:4907.","journal-title":"Cancers (Basel)"},{"key":"7628_CR28","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s11307-015-0866-0","volume":"17","author":"M Dietlein","year":"2015","unstructured":"Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schom\u00e4cker K, et al. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol. 2015;17:575\u201384.","journal-title":"Mol Imaging Biol"},{"key":"7628_CR29","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00330-021-08140-0","volume":"32","author":"S Jentjens","year":"2022","unstructured":"Jentjens S, Mai C, Ahmadi Bidakhvidi N, De Coster L, Mertens N, Koole M, et al. Prospective comparison of simultaneous [68Ga]Ga-PSMA-11 PET\/MR versus PET\/CT in patients with biochemically recurrent prostate cancer. Eur Radiol. 2022;32:901\u201311.","journal-title":"Eur Radiol"},{"key":"7628_CR30","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s12149-018-1275-7","volume":"32","author":"A Ringheim","year":"2018","unstructured":"Ringheim A, Campos Neto GC, Martins KM, Vitor T, da Cunha ML, Baroni RH. Reproducibility of standardized uptake values of same-day randomized 68Ga-PSMA-11 PET\/CT and PET\/MR scans in recurrent prostate cancer patients. Ann Nucl Med. 2018;32:523\u201331.","journal-title":"Ann Nucl Med"},{"key":"7628_CR31","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2967\/jnumed.119.234559","volume":"61","author":"C Kratochwil","year":"2020","unstructured":"Kratochwil C, Giesel FL, Heussel CP, Kazdal D, Endris V, Nientiedt C, et al. Patients resistant against PSMA-Targeting \u03b1-Radiation therapy often harbor mutations in DNA Damage-Repair-Associated genes. J Nucl Med. 2020;61:683\u20138.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07628-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07628-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07628-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:43:27Z","timestamp":1769834607000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07628-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7628"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07628-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Nanjing Medical University (KY20171208-03).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}